NZ783034A - Compositions and methods for decreasing tau expression - Google Patents
Compositions and methods for decreasing tau expressionInfo
- Publication number
- NZ783034A NZ783034A NZ783034A NZ78303416A NZ783034A NZ 783034 A NZ783034 A NZ 783034A NZ 783034 A NZ783034 A NZ 783034A NZ 78303416 A NZ78303416 A NZ 78303416A NZ 783034 A NZ783034 A NZ 783034A
- Authority
- NZ
- New Zealand
- Prior art keywords
- oligonucleotide
- nucleotides
- seq
- moe
- mcgt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Provided herein are compositions and methods for decreasing tau mRNA and protein expression. These compositions and methods are useful in treating tau-related diseases and disorders.
Claims (22)
1. An oligonucleotide comprising a nucleobase sequence that has at least 90% sequence identity to any of the ing nucleobase sequences: G*G*T*T*G*ACATCGTCTGC*C*T*G*T* (SEQ ID NO: 208) or G*G*T*T*G*A mCAT mCGT mCTG mC* mC*T*G*T* (SEQ ID N° 285); wherein C in any of the nucleobase sequences is either cytosine or 5-methylcytosine, and mC is 5-methylcytosine and wherein at least one nucleotide of the oligonucleotide has a 2’- cation, wherein the nucleotides with * have a 2’-O-MOE modification and the nucleotides without * are 2’-deoxynucleosides.
2. The oligonucleotide of claim 1, wherein the internucleoside linkage of the oligonucleotide is either phosphodiester or phosphorothioate linkage.
3. The oligonucleotide of claim 1 or 2, n the oligonucleotide decreases tau mRNA or protein sion independent of RNAse H.
4. The oligonucleotide of any one of claims 1-3, wherein the oligonucleotide ses a base sequence that has at least 95% sequence identity to any of the following nucleobase sequences: G*G*T*T*G*ACATCGTCTGC*C*T*G*T* (SEQ ID NO: 208) or T*G*A mCAT mCGT mCTG mC* mC*T*G*T* (SEQ ID N° 285).
5. The oligonucleotide of any one of claims 1-4, wherein the oligonucleotide comprises any of the following nucleobase sequences: G*G*T*T*G*ACATCGTCTGC*C*T*G*T* (SEQ ID NO: 208) or G*G*T*T*G*A mCAT mCGT mCTG mC* mC*T*G*T* (SEQ ID N° 285).
6. The oligonucleotide of any one of claim 1-5, wherein the oligonucleotide consists of any of the following nucleobase sequences G*G*T*T*G*ACATCGTCTGC*C*T*G*T* (SEQ ID NO: 208) or G*G*T*T*G*A mCAT mCGT mCTG mC* mC*T*G*T*(SEQ ID N° 285).
7. The oligonucleotide of any one of claims 1-6, wherein the internucleoside linkage of the oligonucleotide is phosphorothioate linkage.
8. The oligonucleotide of any one of claims 1-7, wherein the oligonucleotide comprises at least five contiguous 2’-deoxynucleosides.
9. The oligonucleotide of any one of claims 1-8, wherein the oligonucleotide decreases tau mRNA or protein expression by activating RNAse H.
10. The oligonucleotide of any one of claims 1-9, n each C in any of the nucleobase sequences is ylcytosine.
11. The oligonucleotide of any one of claims 1-10, n the oligonucleotide comprises one or more 5-methylcytosines.
12. The ucleotide of anyone of claims 1-11, wherein each nucleotide of the oligonucleotide has a 2’-modification.
13. The oligonucleotide of any one of claims 1-12, wherein the oligonucleotide comprises 12 to 30 nucleobases. or comprises 12 to 25 nucleobases or comprises 15 to 20 nucleobases.
14. The oligonucleotide of any one of claims 1-13, wherein the 2’-modification is ed from the group consisting of oro, 2’-deoxy-2’-fluoro, 2’-O-methyl, 2’-O- methoxyethyl (2’-O-MOE), 2’-O-aminopropyl (2’-O-AP), 2’-O-dimethylaminoethyl (2’-ODMAOE ), 2’-O-dimethylaminopropyl (2’-O-DMAP), 2’-O-dimethylaminoethyloxyethyl (2’- O-DMAEOE), and 2’-O-N-methylacetamido (2’-O-NMA).
15. The oligonucleotide of any one of claims 1-14, wherein the 2’-modification is 2’- O-methoxyethyl (2’-O-MOE).
16. The oligonucleotide of any one of claims 1-15, wherein the oligonucleotide is capable of decreasing tau mRNA or protein expression level by at least 30% in vitro.
17. The oligonucleotide of any one of claims 1-16, wherein the oligonucleotide is capable of decreasing tau mRNA or protein expression level by at least 30% in vivo.
18. The oligonucleotide of any one of claims 1-17, wherein the first to fifth nucleotides each se a 2’-O-MOE modified nucleoside, wherein the sixth to fifteenth nucleotides each comprise a xynucleoside, and wherein the sixteenth to twentieth nucleotides each comprise a 2’-O-MOE modified nucleoside.
19. The oligonucleotide of claim 18, wherein the first to fifth nucleotides each comprise a 2’-O-MOE modified nucleoside, wherein the sixth to nth nucleotides each comprise a 2’-deoxynucleoside, and wherein the sixteenth to twentieth nucleotides each comprise a 2’-O-MOE modified nucleoside
20. An oligonucleotide consisting of a nucleobase sequence of: G*G*T*T*G*A mCAT mCGT mCTG mC* mC*T*G*T* (SEQ ID NO 285), n the nucleotides with * are 2’-O-MOE modified nucleotide, wherein mC is 5-methylcytosine, the nucleotides without * are 2’-deoxynucleosides and n internucleoside linkages are phosphorothioate.
21. An ucleotide consisting of a nucleobase ce of: G*G*T*T*G*ACATCGTCTGC*C*T*G*T*(SEQ ID NO: 208), wherein the nucleotides with * are 2’-O-MOE modified nucleotide, wherein C is either cytosine or 5-methylcytosine, the nucleotides without * are xynucleosides and wherein internucleoside es are phosphorothioate.
22. A composition comprising the oligonucleotide of any one of claims 1-21 and a pharmaceutically acceptable carrier. ..\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\kkkkk\kkkkkkkkkkkkkkkkkbv {3333‘ a.3 ‘\..\V\«\x‘I \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\‘.\\\\\\\\\\\\\\\\‘ \\-x.m“\x“.““x“.V“...xxx“ ““mm. m\“\“\““\““\m \M\\\\\\\\\\\\\\\\\\\\\
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562270165P | 2015-12-21 | 2015-12-21 | |
| NZ743231A NZ743231B2 (en) | 2016-12-19 | Compositions and methods for decreasing tau expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ783034A true NZ783034A (en) | 2025-07-25 |
| NZ783034B2 NZ783034B2 (en) | 2025-10-29 |
Family
ID=
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4455285A3 (en) | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof | |
| WO2020219981A3 (en) | Oligonucleotide compositions and methods of use thereof | |
| FI4220360T3 (en) | OLIGONUCLEOTIDES FOR PATERNAL UBE3A EXPRESSION | |
| EP4527459A3 (en) | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof | |
| JP2013226147A5 (en) | ||
| JP2018138020A (en) | Polycomb-associated non-coding rnas | |
| JP2018512041A5 (en) | ||
| JP2016116520A5 (en) | ||
| JP2018512110A5 (en) | ||
| MX2010009195A (en) | Ultra-small rnas as toll-like receptor-3 antagonists. | |
| JP2016522674A5 (en) | ||
| WO2014025887A1 (en) | Selective reactivation of genes on the inactive x chromosome | |
| WO2005089287A3 (en) | Methods and compositions for the specific inhibition of gene expression by double-stranded rna | |
| EA201100813A1 (en) | PHARMACEUTICAL COMPOSITION | |
| JP2015523853A5 (en) | ||
| JP2016521556A5 (en) | ||
| RU2014121304A (en) | INHIBITION OF EXPRESSION OF VIRAL GENES | |
| PH12021551025A1 (en) | 5-halouracil-modified micrornas and their use in the treatment of cancer | |
| JP2023503635A (en) | Methods of synthesizing RNA molecules | |
| PE20242176A1 (en) | PMP22-TARGETING COMPOUNDS FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH DISEASE | |
| PH12021551544A1 (en) | Oligomeric nucleic acid molecule and application thereof | |
| WO2021262919A3 (en) | 5-halouracil-modified micrornas and their use in the treatment of cancer | |
| KR20150130444A (en) | MicroRNA-BASED APPROACH TO TREATING MALIGNANT PLEURAL MESOTHELIOMA | |
| NZ783034B2 (en) | Compositions and methods for decreasing tau expression | |
| JP2020515625A5 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20251124 |